• The total number of incident cases across the countries under study will increase by 18% from 16,156 in 2016 to 19,110 in 2026
  • Immunization with the HPV vaccine or HPV screening  would be the major factors reducing the age adjusted risk of cervical cancer across countries considered in this analysis.
  • We assume that in the less developed countries under study, there will be a shift in the stage distribution at diagnosis towards earlier stages, attributable to improving healthcare/screening services in these countries.

Table of contents

  • Cervical Cancer - Epidemiology - Americas Data
    • Introduction
      • Key Findings
        • Overview
          • Incidence of Cervical Cancer per 100,000 Women of All Ages in 2016 and 2026
          • Depiction of the Patient Flow in Cervical Cancer in the Americas, 2016
          • Relative Sizes of the Contributing Factors to the Trend in Incident Cases of Cervical Cancer over the Next 10 Years
          • Number of Incident Cases of Cervical Cancer Avoided Over the Period 2016-2026 Across the Countries Under Study
      • Epidemiology Data
      • Methods
        • Newly Diagnosed Incidence
        • Stage Distribution
        • Diagnosed Prevalence
        • Recurrent Incidence
        • Drug-Treatable Populations
      • Reference Materials
        • Literature Review
          • Studies Included in the Analysis of Cervical Cancer
        • Risk/Protective Factors
          • Risk/Protective Factors for Cervical Cancer
        • Bibliography

    Author(s): Nishant Kumar, MPH; Johnson Olabisi, MBBS, MSc

    Nishant is a senior epidemiologist and head of oncology within the epidemiology team at Decision Resources Group. He also covers some CNS diseases, including Alzheimer’s disease and dementia. His key interests are developing interactive patient flows, and modelling disease progression to forecast commercially relevant drug-treatable incident and prevalent populations. Nishant also spends a lot of time collaborating with clients to help answer more specific questions through custom work and consulting projects.

    His qualifications include an MSc in Public Health with specialization in epidemiology and statistics from King’s College London, and a BSc in Medical Studies from the University of Birmingham.

    Johnson joined Decision Resources Group (DRG) in 2015 and with the Epidemiology team develops epidemiological populations forecasts for different infectious and non-communicable diseases with his particular interests in the oncology space.

    Prior to joining DRG, he trained as a community physician where he was involved in primary (patient) care, primary health care and various community research & activities. He has also supervised and coordinated various governmental and non-governmental public health projects. Johnson holds a Masters of Science in Public Health (Health Economics) degree from the London School of Hygiene and Tropical Medicine with a Masters in Epidemiology and Medical Statistics & a Medical degree from the University of Ibadan, Nigeria.